TENEBLU Film-coated tablet Ref.[51008] Active ingredients: Teneligliptin

Source: Web Search  Revision Year: 2021  Publisher: <u>Details of Manufacturer:</u> SYNOKEM PHARMACEUTICALS LTD., Plot No. 56-57, Sector 6A, I.I.E. Sidcul, Ranipur, Haridwar – 249403. Uttarakhand. <u>Marketed by:</u> BLUE CROSS LABORATORIES PVT LTD., A-12, ...

Product name and form

Teneligliptin Tablets IP 20 mg.

(Brand Name: TENEBLU Tablets).

Pharmaceutical Form

Dosage Form: Tablets.

Dosage Strength: Teneligliptin 20 mg per tablet.

Qualitative and quantitative composition

Each film-coated tablet contains: Teneligliptin Hydrobromide Hydrate equivalent to Teneligliptin 20 mg.

Excipients q.s.

Colours: Ferric oxide yellow USP-NF and Titanium Dioxide IP.

Active Ingredient Description
Teneligliptin

Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor. It acts as a competitive reversible inhibitor of DPP-4 and decreases the degradation of incretins, especially GLP-1, thereby improving hyperglycemia by stimulating insulin secretion and suppressing glucagon secretion in a glucose-dependent manner (no or negligible risk of hypoglycemia).

List of Excipients

Pack sizes and marketing

Marketing authorization holder

Details of Manufacturer: SYNOKEM PHARMACEUTICALS LTD., Plot No. 56-57, Sector – 6A, I.I.E. Sidcul, Ranipur, Haridwar – 249403. Uttarakhand.

Marketed by: BLUE CROSS LABORATORIES PVT LTD., A-12, M.I.D.C., NASHIK – 422 010.

Regd. Off.: Peninsula Chambers, G. K. Marg, Mumbai – 400 013.

Marketing authorization dates and numbers

Mfg. Lic. No.: 27/UA/2018

Date of FDA Product Permission: 20/11/2018

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.